Summary of Zymeworks Inc. Q1 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $2.4 million for Q1 2026, a significant drop from $27.1 million in Q1 2025, primarily due to nonrecurring clinical milestones achieved in the previous year.

Operating Expenses: $49.5 million, down from $52.7 million in the prior year, attributed to reduced third-party program costs and lower general and administrative expenses.

Net Loss: $44.2 million, compared to a net loss of $22.6 million in Q1 2025, largely due to decreased revenue.

Cash Position: $403.8 million as of March 31, 2026, up from $270.6 million at year-end 2025, providing a strong cash runway expected to fund operations beyond 2028.

Share Repurchase Program: Approximately $95.8 million utilized to buy back 3.93 million shares at an average price of $24.37 per share.

2Strategic Updates and Business Highlights

Regulatory Milestones: PDUFA date for zanatumab in first-line GEA set for August 25, 2026, with significant milestone payments expected from partners Jazz and BeiGene.

ADC Portfolio Development: Progress in the pan-RAS ADC platform, with promising preclinical data presented at AACR, including three new RAS-targeting ADC candidates.

Leadership Changes: Strengthened leadership team with new appointments, including a General Counsel from Pfizer, aimed at enhancing strategic capital allocation and deal-making capabilities.

3Forward Guidance and Outlook

Anticipation of milestone payments totaling $440 million upon potential approvals of zanatumab in multiple regions.

Continued focus on advancing clinical programs, particularly ZW191 and ZW251, with updates expected at upcoming medical meetings.

Guidance for an IND filing for ZW1528 pushed to 2027, allowing for deeper understanding of IL-33 biology.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Significant year-over-year revenue decrease raises concerns about the sustainability of income streams.

Increased Net Loss: The widening net loss may indicate challenges in managing expenses relative to revenue generation.

Market Pressures: Jazz's comments on MFN pricing headwinds for Zahera could impact royalty revenues from international markets.

Competitive Landscape: The oncology space remains highly competitive, particularly for ZW191, which may affect the speed and scale of development without partnerships.

5Notable Q&A Insights

Data Cadence: Management indicated a steady flow of updates expected throughout 2026, particularly from oncology meetings.

Partnership Strategy: Ongoing discussions for partnerships to share capital and risk, especially for advancing ZW191 and other assets.

Clinical Development Focus: ZW191 shows strong efficacy in challenging patient populations, with plans to optimize dosing and explore combination therapies.

Pan-RAS ADC Development: The company is strategically positioning multiple ADCs across different tumor types, emphasizing flexibility and optionality in development paths. Overall, Zymeworks is navigating a challenging financial landscape while making strategic advancements in its clinical pipeline and maintaining a robust cash position to support future growth.